Physician profile
William D Dodge
NPI 1942233523
$2,215.15
in general payments reported to CMS, 2019-2025
26 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $111 · 2021: $161 · 2022: $260 · 2023: $628 · 2024: $475 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $293.86 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $290.64 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $284.50 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $225.69 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $163.56 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $149.58 | 2019-2025 | |
| Baxter Healthcare | $105.00 | 2022 | |
| Abbvie INC. | $104.44 | 2023-2025 | Ubrelvy, Linzess, Viberzi |
| Exact Sciences Corporation | $93.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $60.37 | 2023-2024 | Spravato |
| Boston Scientific Corporation | $56.75 | 2023 | Wavewriter Alpha Prime 16 |
| Sanofi Pasteur INC. | $48.28 | 2025 | |
| Idorsia Pharmaceuticals US INC | $43.10 | 2023 | Quviviq |
| Genentech USA, INC. | $39.52 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.98 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $35.86 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.64 | 2023 | Ofev |
| Merck Sharp & Dohme LLC | $22.87 | 2019 | |
| Dexcom, INC. | $21.80 | 2024 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $21.68 | 2023 | |
| Astellas Pharma US INC | $19.56 | 2025 | Veozah |
| Adlon Therapeutics L.P. | $15.23 | 2020 | |
| Horizon Therapeutics Plc | $14.91 | 2022 | |
| Inspire Medical Systems, INC. | $14.49 | 2025 | Inspire |
| Wright Medical Technology, INC. | $13.39 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dodge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.